397 related articles for article (PubMed ID: 38139341)
21. NAFLD and MAFLD as emerging causes of HCC: A populational study.
Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
[TBL] [Abstract][Full Text] [Related]
22. Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm.
Chua D; Low ZS; Cheam GX; Ng AS; Tan NS
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499091
[TBL] [Abstract][Full Text] [Related]
23. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
24. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
[TBL] [Abstract][Full Text] [Related]
25. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
26. The microbial metabolome in metabolic-associated fatty liver disease.
Li M; Rajani C; Zheng X; Jia W
J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
[TBL] [Abstract][Full Text] [Related]
27. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.
Ismaiel A; Dumitrascu DL
Eur J Clin Invest; 2020 Oct; 50(10):e13331. PubMed ID: 32589269
[TBL] [Abstract][Full Text] [Related]
28. Associations of urinary organophosphate esters metabolites and diet quality with nonalcoholic/metabolic dysfunction-associated fatty liver diseases in adults.
Aimuzi R; Xie Z; Qu Y; Jiang Y; Luo K
Ecotoxicol Environ Saf; 2023 Apr; 254():114720. PubMed ID: 36889207
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
Fassio E; Barreyro FJ; Pérez MS; Dávila D; Landeira G; Gualano G; Ruffillo G
World J Hepatol; 2022 Feb; 14(2):354-371. PubMed ID: 35317172
[TBL] [Abstract][Full Text] [Related]
30. MAFLD: an optimal framework for understanding liver cancer phenotypes.
Crane H; Gofton C; Sharma A; George J
J Gastroenterol; 2023 Oct; 58(10):947-964. PubMed ID: 37470858
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy.
Zheng Y; Wang S; Wu J; Wang Y
J Transl Med; 2023 Jul; 21(1):510. PubMed ID: 37507803
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
Chen S; Guo H; Xie M; Zhou C; Zheng M
Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
[TBL] [Abstract][Full Text] [Related]
33. Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
Lazo-de-la-Vega-Monroy ML; Preciado-Puga MD; Ruiz-Noa Y; Salum-Zertuche M; Ibarra-Reynoso LD
Clin Res Hepatol Gastroenterol; 2023 May; 47(6):102137. PubMed ID: 37149032
[TBL] [Abstract][Full Text] [Related]
34. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.
Kawaguchi T; Tsutsumi T; Nakano D; Eslam M; George J; Torimura T
Clin Mol Hepatol; 2022 Apr; 28(2):150-163. PubMed ID: 34753279
[TBL] [Abstract][Full Text] [Related]
35. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
36. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
37. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.
Bhardwaj M; Mazumder PM
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38861011
[TBL] [Abstract][Full Text] [Related]
38. Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC.
Longo M; Paolini E; Meroni M; Dongiovanni P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920670
[TBL] [Abstract][Full Text] [Related]
39. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis.
Liao Y; Wang L; Liu F; Zhou Y; Lin X; Zhao Z; Xu S; Tang D; Jiao Y; Yang L; Yu W; Gao P
Front Endocrinol (Lausanne); 2023; 14():1078149. PubMed ID: 36761200
[TBL] [Abstract][Full Text] [Related]
40. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
